← Eichor
Condition: Jak2 Mutation Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Jak2 Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Evaluation of the Pathobiology of CALR-mutated MPN Cells
Phase N/A · 2 location(s) · Wake Forest University Health Sciences · NCT06480591Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis
Phase 1 · 1 location(s) · Brigham and Women's Hospital · NCT07249840Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
Phase 2 · 4 location(s) · William Shomali · NCT03801434
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.